February 22, 2013 8:59 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that it hasentered into definitive agreements with an institutional investor for afinancing of up to $2.1 million in gross proceeds. Under the terms of theagreements, Oxygen will issue registered shares of Series B-1 convertiblepreferred stock (the “Series B-1 Stock”) for $1.6 million in gross proceedsand unregistered shares of Series B-2 convertible preferred stock (the “SeriesB-2 Stock” and, together with the Series B-1 Stock, the “Preferred Stock”) for$0.5 million in gross proceeds, which are convertible into common stock of theCompany at $0.25 per share. The transaction also provides for the issuance bythe Company of unregistered warrants to purchase up to 12,600,000 shares ofcommon stock of the Company with an initial exercise price of $0.50.The offering is expected to close on or about Wednesday, February 27, 2013,subject to the satisfaction of customary closing conditions. A more completedescription of the terms and conditions of the financing will be available inthe Form 8-K to be filed by the Company with the Securities and ExchangeCommission (the “SEC”).
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.